MX2021005144A - Suspension de edaravona para administracion oral. - Google Patents
Suspension de edaravona para administracion oral.Info
- Publication number
- MX2021005144A MX2021005144A MX2021005144A MX2021005144A MX2021005144A MX 2021005144 A MX2021005144 A MX 2021005144A MX 2021005144 A MX2021005144 A MX 2021005144A MX 2021005144 A MX2021005144 A MX 2021005144A MX 2021005144 A MX2021005144 A MX 2021005144A
- Authority
- MX
- Mexico
- Prior art keywords
- oral administration
- edaravone suspension
- edaravone
- suspension
- burden
- Prior art date
Links
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 title abstract 2
- 229950009041 edaravone Drugs 0.000 title abstract 2
- 239000000725 suspension Substances 0.000 title abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018207646 | 2018-11-02 | ||
| PCT/JP2019/043013 WO2020091036A1 (ja) | 2018-11-02 | 2019-11-01 | 経口投与用エダラボン懸濁剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005144A true MX2021005144A (es) | 2021-07-15 |
Family
ID=70463399
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005144A MX2021005144A (es) | 2018-11-02 | 2019-11-01 | Suspension de edaravona para administracion oral. |
| MX2023009973A MX2023009973A (es) | 2018-11-02 | 2021-04-30 | Suspension de edaravona para administracion oral. |
| MX2024000663A MX2024000663A (es) | 2018-11-02 | 2021-04-30 | Suspension de edaravona para administracion oral. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009973A MX2023009973A (es) | 2018-11-02 | 2021-04-30 | Suspension de edaravona para administracion oral. |
| MX2024000663A MX2024000663A (es) | 2018-11-02 | 2021-04-30 | Suspension de edaravona para administracion oral. |
Country Status (20)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019167178A1 (ja) * | 2018-02-28 | 2019-09-06 | 田辺三菱製薬株式会社 | 3-メチル-1-フェニル-2-ピラゾリン-5-オン原薬の分析方法、筋萎縮性側索硬化症の治療および筋萎縮性側索硬化症の進行抑制、ならびに、3-メチル-1-フェニル-2-ピラゾリン-5-オン原薬を含む薬剤の製造方法 |
| BR112021008197A2 (pt) | 2018-11-02 | 2021-08-03 | Mitsubishi Tanabe Pharma Corporation | suspensão de edaravone para administração oral |
| US11826352B2 (en) | 2018-11-02 | 2023-11-28 | Mitsubishi Tanabe Pharma Corporation | Edaravone suspension for oral administration |
| IN201921028874A (cg-RX-API-DMAC7.html) * | 2019-07-18 | 2021-01-22 | ||
| JPWO2022102737A1 (cg-RX-API-DMAC7.html) | 2020-11-12 | 2022-05-19 | ||
| US12194025B2 (en) | 2020-11-12 | 2025-01-14 | Mitsubishi Tanabe Pharma Corporation | Pharmaceutical composition for oral administration of edaravone and method of administering same |
| GB202103807D0 (en) | 2021-03-18 | 2021-05-05 | Johnson Matthey Plc | A crystalline salt of edaravone, processes for the preparation and use thereof |
| EP4473965A4 (en) | 2022-02-03 | 2026-01-07 | Mitsubishi Tanabe Pharma Corp | MEDICAL AGENT FOR THE TREATMENT OR SUPPRESSION OF THE PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS |
| WO2024005187A1 (ja) | 2022-07-01 | 2024-01-04 | 田辺三菱製薬株式会社 | 組成物、およびエダラボンの応答可能性の評価方法 |
| WO2024172852A1 (en) | 2023-02-16 | 2024-08-22 | Slayback Pharma Llc | Stable pharmaceutical compositions of edaravone |
| CN118178328A (zh) * | 2024-03-21 | 2024-06-14 | 药云(西安)医药技术有限公司 | 依达拉奉包埋物制备方法与其口服制剂 |
| US20260130849A1 (en) * | 2024-11-13 | 2026-05-14 | Tulex Pharmaceuticals, Inc. | Edaravone Oral Solution Compositions |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61263917A (ja) | 1985-05-20 | 1986-11-21 | Mitsubishi Yuka Yakuhin Kk | 脳機能正常化剤 |
| JPH07121861B2 (ja) | 1986-11-25 | 1995-12-25 | 三菱化学株式会社 | 3−メチル−1−フエニル−2−ピラゾロン−5−オンを含有する安定な注射剤 |
| JPH0531523A (ja) | 1991-07-26 | 1993-02-09 | Aichi Steel Works Ltd | ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置 |
| JP3402195B2 (ja) * | 1997-05-14 | 2003-04-28 | 千寿製薬株式会社 | 再分散性の良い水性懸濁液剤 |
| JPH1120463A (ja) | 1997-06-30 | 1999-01-26 | Zexel Corp | 車両用デュアルエアコン |
| ES2248144T3 (es) | 2000-10-24 | 2006-03-16 | Mitsubishi Pharma Corporation | Medicamentos para tratar la esclerosis lateral amiotrofica (ela). |
| JP2004091441A (ja) * | 2002-09-04 | 2004-03-25 | Mitsubishi Pharma Corp | ピラゾロン誘導体を含有する経口投与製剤 |
| EP1714960B1 (en) | 2004-02-09 | 2018-03-28 | Mitsubishi Tanabe Pharma Corporation | Novel therapeutic agent for amyotrophic lateral sclerosis (als) or disease attributable to als |
| JP5836004B2 (ja) | 2010-08-12 | 2015-12-24 | 日新化成株式会社 | 可溶化剤 |
| CN102824356A (zh) | 2012-09-25 | 2012-12-19 | 江西中医学院 | 一种黄芩苷纳晶混悬剂、纳晶干粉及其制备方法 |
| US9642843B2 (en) | 2013-02-27 | 2017-05-09 | The Regents Of The University Of Michigan | Pharmaceutical compounds and use of same in cancer and tauopathies |
| JP6336246B2 (ja) * | 2013-03-13 | 2018-06-06 | 大同化成工業株式会社 | ナノ粒子化製剤及びその製造方法 |
| CN105878171A (zh) * | 2014-12-22 | 2016-08-24 | 南京海恒医药科技有限公司 | 一种依达拉奉新制剂及其制备方法 |
| CN107205935A (zh) | 2015-01-20 | 2017-09-26 | 默克专利股份有限公司 | 用聚乙烯醇作载体聚合物的化合物固体分散体 |
| EP3427724A4 (en) | 2016-03-10 | 2019-11-13 | Sumitomo Dainippon Pharma Co., Ltd. | COMPOSITION WITH FINE PARTICLES AND METHOD FOR THE MANUFACTURE THEREOF |
| CN109125261B (zh) * | 2016-03-16 | 2021-11-30 | 苏州澳宗生物科技有限公司 | 依达拉奉剂型 |
| EP3785703A1 (en) | 2017-01-17 | 2021-03-03 | Treeway TW001 B.V. | Treatment comprising oral or gastric administration of edaravone |
| BR112019014712A2 (pt) * | 2017-01-17 | 2020-02-18 | Treeway Tw001 B.V. | Tratamento médio que compreende a administração entérica de edaravona |
| KR20200024868A (ko) * | 2017-07-06 | 2020-03-09 | 트리웨이 티더블유001 비.브이. | 산화성 스트레스-매개 신경퇴행성 질환의 경구 치료에 사용하기 위한 에다라본의 용도 |
| BR112021008197A2 (pt) * | 2018-11-02 | 2021-08-03 | Mitsubishi Tanabe Pharma Corporation | suspensão de edaravone para administração oral |
| IN201921028874A (cg-RX-API-DMAC7.html) * | 2019-07-18 | 2021-01-22 |
-
2019
- 2019-11-01 BR BR112021008197-6A patent/BR112021008197A2/pt unknown
- 2019-11-01 PT PT198807703T patent/PT3875085T/pt unknown
- 2019-11-01 KR KR1020217016462A patent/KR20210087490A/ko active Pending
- 2019-11-01 AU AU2019369843A patent/AU2019369843A1/en not_active Abandoned
- 2019-11-01 CN CN202311552338.3A patent/CN117379369A/zh active Pending
- 2019-11-01 CN CN202311552339.8A patent/CN117379370A/zh active Pending
- 2019-11-01 WO PCT/JP2019/043013 patent/WO2020091036A1/ja not_active Ceased
- 2019-11-01 IL IL319280A patent/IL319280A/en unknown
- 2019-11-01 AR ARP190103206A patent/AR116967A1/es unknown
- 2019-11-01 EP EP19880770.3A patent/EP3875085B1/en active Active
- 2019-11-01 HU HUE19880770A patent/HUE068117T2/hu unknown
- 2019-11-01 ES ES19880770T patent/ES2991523T3/es active Active
- 2019-11-01 CN CN202311552337.9A patent/CN117398346A/zh active Pending
- 2019-11-01 SG SG11202104365QA patent/SG11202104365QA/en unknown
- 2019-11-01 JP JP2020554977A patent/JP7274502B2/ja active Active
- 2019-11-01 CN CN201980072370.7A patent/CN112969459B/zh active Active
- 2019-11-01 EP EP24181935.8A patent/EP4420724A3/en active Pending
- 2019-11-01 IL IL282773A patent/IL282773B2/en unknown
- 2019-11-01 MX MX2021005144A patent/MX2021005144A/es unknown
- 2019-11-01 FI FIEP19880770.3T patent/FI3875085T3/fi active
- 2019-11-01 PL PL19880770.3T patent/PL3875085T3/pl unknown
- 2019-11-01 TW TW108139797A patent/TWI924629B/zh active
- 2019-11-01 DK DK19880770.3T patent/DK3875085T3/da active
-
2020
- 2020-05-12 US US16/872,741 patent/US10987341B2/en active Active
-
2021
- 2021-03-26 US US17/213,501 patent/US11241416B2/en active Active
- 2021-04-30 PH PH12021550988A patent/PH12021550988A1/en unknown
- 2021-04-30 MX MX2023009973A patent/MX2023009973A/es unknown
- 2021-04-30 MX MX2024000663A patent/MX2024000663A/es unknown
- 2021-12-23 US US17/560,493 patent/US11478450B2/en active Active
-
2022
- 2022-09-22 US US17/934,234 patent/US11957660B2/en active Active
-
2023
- 2023-05-01 JP JP2023075654A patent/JP7828317B2/ja active Active
-
2024
- 2024-03-26 US US18/616,227 patent/US12599586B2/en active Active
-
2025
- 2025-07-21 AU AU2025205635A patent/AU2025205635A1/en active Pending
- 2025-10-06 JP JP2025168147A patent/JP2026010001A/ja active Pending
-
2026
- 2026-04-13 US US19/646,107 patent/US20260232635A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550988A1 (en) | Edaravone suspension for oral administration | |
| TWD193695S (zh) | 口腔保健用具(三) | |
| TWD208079S (zh) | 鼻管組合及其配件 | |
| TWD200678S (zh) | 口腔內攝影機 | |
| TWD222134S (zh) | 病患連接裝置 | |
| TWD192740S (zh) | 病患連接裝置的頭罩帶 | |
| TWD197207S (zh) | 口腔保健用具的替換頭部(一) | |
| TWD216422S (zh) | 醫療用通氣管 | |
| TWD197206S (zh) | 口腔保健用具的替換頭部(三) | |
| TWD200284S (zh) | 口腔保健用具 | |
| IL273931A (en) | Patient care system | |
| SG10201807070YA (en) | Respiratory mask with nasogastric tube path | |
| TWD190209S (zh) | 心電圖機 | |
| TWD192266S (zh) | 藥劑輸注裝置之部分 | |
| TWD200143S (zh) | 口腔保健器具(三) | |
| WO2018067520A3 (en) | Therapeutic agents and methods: | |
| WO2020264130A8 (en) | Oral care device for intubation | |
| TWD191352S (zh) | 剝線器之部分 | |
| MY208219A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof | |
| TWD196684S (zh) | 口腔保健用具的跟蹤模組(一) | |
| MX2021010207A (es) | Formulacion farmaceutica de liberacion extendida. | |
| UA118587C2 (uk) | Фармацевтично прийнятні солі енантіомерів пірліндолу для застосування в медицині | |
| MX2024009135A (es) | Sistema de productos para el cuidado personal para etapas del desarrollo humano. | |
| TWD201276S (zh) | 牙科相機 | |
| MX2020007627A (es) | Uso de la carrimicina o de sus ingredientes activos. |